Log in

Relevant bibliographies by topics / Xultophy

Contents

Journal articles

Academic literature on the topic 'Xultophy'

Author: Grafiati

Published: 4 June 2025

Last updated: 15 July 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Xultophy.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Xultophy"

1

T, Fujikawa, Kato Y, Bando H, et al. "The Administration of Xultophy for Diabetic Patients on Hemodialysis." Diabetes Research: Open Access 2, no. 3 (2020): 72–78. http://dx.doi.org/10.36502/2020/droa.6172.

Full text

Abstract:

Background: Recent diabetic treatments include Insulin Degludec/ liraglutide (IDeg/Lira, Xultophy) in clinical practice. Authors have continued clinical research concerning diabetes, chronic renal failure, dialysis, and others. Subjects and Methods: Ten patients with type 2 diabetes mellitus (T2DM) undergoing hemodialysis were investigated. They showed that ages 74.5 ± 5.9 years, M/F=6/4, BMI 21.1± 3.8kg/m2, hemodialysis duration 8.1 ± 5.7 years. At the beginning, fundamental data were Cre 8.2 ± 1.9 mg/dL, HbA1c 6.5 ± 0.8%. Xultophy was started on 5-12 doses and continued for 6 months with the

APA, Harvard, Vancouver, ISO, and other styles

2

Bando MD, Hiroshi, Tatsuo Yasuoka MD, Kenji Hayashi MD, et al. "Effective and convenient treatment of Xultophy with lower doses for elderly diabetic patient." Endocrinology&Metabolism International Journal 9, no. 2 (2021): 32–36. http://dx.doi.org/10.15406/emij.2021.09.00305.

Full text

Abstract:

The case is an 82-year-old female patient with Type 2 Diabetes Mellitus (T2DM) for 22 years. She developed right empyema in early January, 2021 and was treated by antibiotics and CT-guided drainage. After improving the status, she was transferred to Hayashi hospital, Tokushima, Japan. Treatment for T2DM was initially multiple daily insulin injection (MDI), but it could not continue because of injection several times a day by the family. Then, Xultophy was started once a day, which brought satisfactory glucose variability with lower doses. Consequently, Xultophy would be effective and useful ag

APA, Harvard, Vancouver, ISO, and other styles

3

Bando, Hiroshi, Hiroko Ogawa, Shinji Nagahiro, Miwako Nakanishi, and Osami Watanabe. "Satisfactory Control for Glucose Profile by Combined Agents of Xultophy with A Small Dose." Diabetes Research: Open Access 3, no. 2 (2021): 23–29. http://dx.doi.org/10.36502/2021/droa.6180.

Full text

Abstract:

The patient was a 74-year-old female with type 2 diabetes mellitus (T2DM) treated on Humalog mix 25 twice a day. As social history, she has worked long years for growing and harvesting lotus roots. It gives physically heavy loading, which brings unstable glycemic daily control. She had to titrate minute regulation every time. For stable glucose variability, the treatment was changed to Xultophy, which is a specific combined agent of Insulin Degludec and Liraglutide (IDeg/Lira) once a day. Then, detailed glucose monitoring showed a better daily profile of blood glucose, irrespective of heavy or

APA, Harvard, Vancouver, ISO, and other styles

4

Bando, Hiroshi. "Satisfactory Rapid Response to Xultophy Associated with Meal Tolerance Test (MTT) by Carbohydrate Loading." Asploro Journal of Biomedical and Clinical Case Reports 4, no. 2 (2021): 145–52. http://dx.doi.org/10.36502/2021/asjbccr.6245.

Full text

Abstract:

The case is a 69-year-old male patient with Type 2 Diabetes Mellitus (T2DM) for 21 years. His diabetic control was not so satisfactory, and his HbA1c value increased in spring 2021. Then, he started Xultophy (IDegLira), which includes a fixed ratio of two agents of basal degludec and liraglutide. Just after providing Xultophy, the daily profile of blood glucose decreased from 179-400 mg/dL to 112-171 mg/dL, with remarkable clinical efficacy. He usually takes 80g of carbohydrates in breakfast, and the meal tolerance test (MTT) was challenged. As carbohydrate loading was given 100-75-50-0%, post

APA, Harvard, Vancouver, ISO, and other styles

5

Chaplin, Steve, and Vinod Patel. "Xultophy: combination therapy for the treatment of type 2 diabetes." Prescriber 26, no. 17 (2015): 32–34. http://dx.doi.org/10.1002/psb.1382.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

H, Bando, Kato Y, Kato Y, Matsuzaki S, Waka S, and Ogura K. "Changed Diabetic Treatment from Multiple Daily Injection (MDI), Dulaglutide to Xultophy." Asploro Journal of Biomedical and Clinical Case Reports 4, no. 1 (2021): 77–83. http://dx.doi.org/10.36502/2021/asjbccr.6233.

Full text

Abstract:

The patient is a 56-year old (yo) female with type 2 diabetes mellitus (T2DM). Medical histories include persisting T2DM from 35yo, renal stone at 43yo, hypertension from 45yo, photocoagulation for retinopathy on 54yo. An incidentaloma was found in the left adrenal gland, where endocrinological exams were negative for functional tumor. Her diabetic control situation became worse with HbA1c > 10%, then the treatment has been changed from multiple daily injection (MDI), Dulaglutide to Xultophy which is combined agents of degludec and liraglutide (IDegLira). It was provided 10-18 doses daily,

APA, Harvard, Vancouver, ISO, and other styles

7

Hiroshi, Bando, Kato Yoshinobu, Kato Yoshikane, Matsuzaki Sayuri, Waka Shinnichi, and Ogura Katsunori. "Changed Diabetic Treatment from Multiple Daily Injection (MDI), Dulaglutide to Xultophy." Asploro Journal of Biomedical and Clinical Case Reports 4, no. 1 (2021): 77–83. https://doi.org/10.36502/2021/ASJBCCR.6233.

Full text

Abstract:

The patient is a 56-year old (yo) female with type 2 diabetes mellitus (T2DM). Medical histories include persisting T2DM from 35yo, renal stone at 43yo, hypertension from 45yo, photocoagulation for retinopathy on 54yo. An incidentaloma was found in the left adrenal gland, where endocrinological exams were negative for functional tumor. Her diabetic control situation became worse with HbA1c > 10%, then the treatment has been changed from multiple daily injection (MDI), Dulaglutide to Xultophy which is combined agents of degludec and liraglutide (IDegLira). It was provided 10-18 doses daily,

APA, Harvard, Vancouver, ISO, and other styles

8

H, Bando. "Direction for Basal Insulin Therapy by Once Daily Injection in the Clinical Practice." Diabetes Research: Open Access 3, no. 1 (2021): 11–15. http://dx.doi.org/10.36502/2021/droa.6177.

Full text

Abstract:

American Diabetes Association (ADA) has announced the new version of the standards of Medical Care in Diabetes-2021. The guideline of the diabetic patients with Older Adults seems to be used for a wide range of clinical practice. Among them, several impressive comments were found, where “Once-daily basal insulin injection therapy is associated with minimal side effects and maybe a reasonable option in many elder patients”. Recent topic includes Dual Action of Liraglutide and insulin degludec (DUAL) studies, and Xultophy has shown beneficial efficacy. Consequently, the trend would be developed

APA, Harvard, Vancouver, ISO, and other styles

9

Kawata, Takafumi, Hiroshi Bando, Yoshinobu Kato, et al. "Glucose-lowering efficacy of Xultophy with low doses by FreeStyle Libre as continuous glucose monitoring (CGM)." International Medicine 3, no. 2 (2021): 65. http://dx.doi.org/10.5455/im.59761.

Full text

APA, Harvard, Vancouver, ISO, and other styles

10

Bando, Hiroshi. "Impressive clinical course of diabetic patient with various medical problems and remarkable improvement by insulin degludec and liraglutide (Xultophy)." MOJ Clinical & Medical Case Reports 10, no. 2 (2020): 48–51. http://dx.doi.org/10.15406/mojcr.2020.10.00341.

Full text

APA, Harvard, Vancouver, ISO, and other styles

More sources

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!